Articles From: Exelis appoints Peter Martin as vice president and general manager of its electronic attack and release systems business to Exelon Generation To Build Two New Natural Gas Units In Texas


Exelis ( NYSE: XLS ) has appointed Peter Martin to lead its electronic attack and release systems business on Long Island, New York.
Sign-up for Exelis appoints Peter Martin as vice president and general manager of its electronic attack and release systems business investment picks
Exelis ( NYSE: XLS ) has been awarded a follow-on contract from Lockheed Martin to manufacture composite missile bodies and structures for Lots 11 and 12 of the Joint Air-to-Surface Standoff Missile (JASSM ® ). The value of the award is approximately $20 million.
Sign-up for Exelis Awarded Follow-on Contract for Lockheed Martin’s JASSM investment picks
Exelis ( NYSE: XLS ) has been awarded a $10.3 million sole source U.S. Air Force contract to insert a modern data storage and retrieval technology into the Strategic Automated Command Control System (SACCS). The SACCS provides orders and pass codes authentication for Air Force nuclear weapons platforms, bombers, and support units.
Sign-up for Exelis awarded US Air Force contract to upgrade Strategic Automated Command Control System digital memory technology investment picks
The Board of Directors for Exelis ( NYSE:XLS ) has declared a cash dividend of $0.1033 per share for the fourth quarter of 2014.
Sign-up for Exelis Board Approves $0.1033 Per Share Dividend for the Fourth Quarter of 2014 investment picks
The board of directors for Exelis ( NYSE: XLS ) has authorized a share repurchase program.
Sign-up for Exelis Board of Directors Approves $350 Million Share Repurchase Program investment picks
Exelis ( NYSE: XLS ) today announced that Chief Executive Officer and President David Melcher will present at the Credit Suisse Global Industrials Conference in New York City Tuesday, Dec.
Sign-up for Exelis Chief Executive Officer and President David Melcher to present at the 2014 Credit Suisse Global Industrials Conference investment picks
Exelis ( NYSE: XLS ) has received official certification for its AN/ALQ-211(V)9 Advanced Integrated Defensive Electronic Warfare System (AIDEWS) to fly on board Pakistani F-16 fighter aircraft.
Sign-up for Exelis electronic countermeasures pod certified for installation on international F-16 Fighting Falcons investment picks
Exelis ( NYSE: XLS ) reported financial results for the third quarter of 2014.
Sign-up for Exelis reports third-quarter 2014 financial results; revises full-year guidance investment picks
The U.S. Army Contracting Command has awarded Exelis (NYSE: XLS) a task order to deliver a limited quantity of SideHat ® SRW (Solidier Radio Waveform) Applique radios for evaluation.
Sign-up for Exelis SideHat radio to be tested by US Army investment picks
Exelis (NYSE: XLS ) today completed the previously announced separation of its former Mission Systems government services business into a new independent, publicly traded company, Vectrus, Inc. The spin-off has been structured to qualify as a tax-free distribution to Exelis shareholders for U.S. federal tax purposes, except for cash received in lieu of fractional shares.
Sign-up for Exelis successfully completes spin-off of Vectrus, Inc. investment picks
Exelis ( NYSE: XLS ) will announce its 2014 third-quarter financial results at 6:30 a.m. EDT Friday, Oct.
Sign-up for Exelis to announce 2014 third-quarter financial results Oct. 31 investment picks
Exelis (NYSE: XLS) will showcase a variety of its leading defense and information solutions at the 2014 Association of the United States Army (AUSA) Annual Meeting and Exposition in Washington, District of Columbia, Oct.
Sign-up for Exelis to display ready-now affordable solutions and new technologies for the U.S. Army and international customers at 2014 AUSA Annual Meeting investment picks
Exelis ( NYSE: XLS ) will host an investor and analyst event Nov.
Sign-up for Exelis to hold investor and analyst event Nov. 4 investment picks
Exelis ( NYSE: XLS ) will debut Disruptor SRx™ , an adaptive, multifunctional electronic warfare (EW) capability during the Association of Old Crows (AOC) International Symposium and Convention at the Marriott Wardman Park Hotel in Washington, District of Columbia, Oct.
Sign-up for Exelis to Launch Next-Generation Electronic Warfare Capability at AOC Annual Symposium investment picks
Exelis ( NYSE: XLS ) has signed a teaming agreement with Airbus Group to provide advanced missile warning capabilities for U.S. and international F-16 Fighting Falcon aircraft.
Sign-up for Exelis, Airbus partner to provide missile warning capabilities for US and international F-16 aircraft investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that cobimetinib, an Exelixis-discovered compound, will be the subject of a clinical data presentation at the European Society for Medical Oncology (ESMO) 2014 Congress.
Sign-up for Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.
Sign-up for Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib investment picks
Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis.
Sign-up for Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide.
Sign-up for Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer investment picks
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter of 2014 and provided an update on its progress toward delivering upon its key corporate objectives and clinical development milestones.
Sign-up for Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that the enrollment target of 650 patients has been reached for METEOR, the company’s phase 3 pivotal trial of cabozantinib in patients with metastatic renal cell carcinoma (RCC) who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor (TKI). Top-line efficacy and safety data from METEOR are now expected in the second quarter of 2015.
Sign-up for Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 investment picks
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Sign-up for Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 investment picks
Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2014 financial results will be released on Tuesday, November 4, 2014 after the markets close.
Sign-up for Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014 investment picks
Exelon Corporation (NYSE: EXC) announced third quarter 2014 consolidated earnings as follows: Third Quarter “Exelon achieved earnings above our guidance range this quarter, with strong performance from both our utility and generation businesses,” said Christopher M.
Sign-up for Exelon Announces Third Quarter 2014 Results investment picks
2014/10/21
The Board of Directors of Exelon Corporation declared a regular quarterly dividend of $0.31 per share on Exelon’s common stock.
Sign-up for Exelon Corporation Declares Dividend investment picks
2014/12/1
Employee volunteers from across Exelon’s family of companies participated in more than 130 service projects in Illinois, Maryland and Pennsylvania to celebrate #GivingTuesday (December 2). Approximately 1,300 employees volunteered over 9,700 hours to projects in November, including sorting and wrapping toys for the holidays, mentoring students and packaging food for needy families at organizations in the communities Exelon serves.
Sign-up for Exelon Employees Celebrate #GivingTuesday by Volunteering at More Than 130 Community Service Events investment picks
2014/10/8
More than 150 minority- and women-owned business leaders joined an event yesterday to learn more about Exelon’s strategy to increase its spending with diverse suppliers.
Sign-up for Exelon Executives Build Connections with D.C.-Area Minority- and Women-Owned Business Leaders investment picks
KENNETT SQUARE, Pa.
Sign-up for Exelon Generation To Build Two New Natural Gas Units In Texas investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Exelis appoints Peter Martin as vice president and general manager of its electronic attack and release systems business to Exelon Generation To Build Two New Natural Gas Units In Texas
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent